Treats schizophrenia. ANDA 208052, held by Zydus Pharms. Lurasidone Hydrochloride.
As of Nov 16, 2026, ANDA 208052 (Lurasidone Hydrochloride), held by Zydus Pharms, was first approved by FDA on Mar 19, 2019, with 2 approved supplements and 0 published complete response letters.
Lurasidone hydrochloride is indicated for: Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia. Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression). Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression). Lurasidone hydrochloride tablets are an atypical antipsychotic indicated for the treatment of: Schizophrenia in adults and adolescents (13 to 17 years) ( 1, 14.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 19, 2019 | Original application | Approved |
| Lurasidone Hydrochloride20MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride40MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride60MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride80MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride120MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| May 14, 2026 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 21, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 19, 2019 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters